var data={"title":"Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Emily Bergsland, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Mark Feldman, MD, MACP, AGAF, FACG</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Shilpa Grover, MD, MPH, AGAF</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 12, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Zollinger-Ellison (ZES) syndrome is characterized by gastric acid hypersecretion resulting in severe acid-related peptic disease and diarrhea [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/1,2\" class=\"abstract_t\">1,2</a>]. The clinical manifestations and diagnosis of ZES will be reviewed here. The management of ZES is discussed separately. (See <a href=\"topic.htm?path=management-and-prognosis-of-the-zollinger-ellison-syndrome-gastrinoma\" class=\"medical medical_review\">&quot;Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Zollinger-Ellison syndrome (ZES) is caused by secretion of gastrin by duodenal or pancreatic neuroendocrine tumors (gastrinomas). The annual incidence of gastrinomas is 0.5 to 2 per million population [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/3-5\" class=\"abstract_t\">3-5</a>]. Most patients are diagnosed between the ages of 20 and 50, with a higher incidence in men as compared with women [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/6\" class=\"abstract_t\">6</a>]. Approximately 80 percent of gastrinomas are sporadic, but 20 to 30 percent occur in association with multiple endocrine neoplasia type 1 (MEN1) [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/7\" class=\"abstract_t\">7</a>]. (See <a href=\"topic.htm?path=multiple-endocrine-neoplasia-type-1-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis&quot;</a>.)</p><p>Although gastrinomas are one of the most common functional pancreatic neuroendocrine tumors, only 25 percent of gastrinomas arise in the pancreas [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/6,8\" class=\"abstract_t\">6,8</a>]. Approximately 50 to 88 percent of patients with sporadic ZES, and 70 to 100 percent of patients with ZES associated with MEN1, have duodenal gastrinomas. Duodenal gastrinomas are predominantly found in the first part of the duodenum. As compared with pancreatic gastrinomas, duodenal gastrinomas are usually small (&lt;1 cm), are often multiple, and are less likely to have metastasized to the liver at diagnosis (0 to 10 versus 22 to 35 percent) [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/6,7,9,10\" class=\"abstract_t\">6,7,9,10</a>]. In 5 to 15 percent of patients, gastrinomas arise in non-pancreatic, non-duodenal abdominal (stomach, peripancreatic lymph nodes, liver, bile duct, ovary), and extra-abdominal (heart, small cell lung cancer) locations [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/11,12\" class=\"abstract_t\">11,12</a>]. </p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">CLASSIFICATION, NOMENCLATURE, AND HISTOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The World Health Organization (WHO) classifies neuroendocrine tumors (NETs) arising within the digestive system based upon the extent to which they resemble their normal nonneoplastic counterparts (<a href=\"image.htm?imageKey=ONC%2F115945\" class=\"graphic graphic_table graphicRef115945 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/13\" class=\"abstract_t\">13</a>]. (See <a href=\"topic.htm?path=pathology-classification-and-grading-of-neuroendocrine-neoplasms-arising-in-the-digestive-system#H369507898\" class=\"medical medical_review\">&quot;Pathology classification, and grading of neuroendocrine neoplasms arising in the digestive system&quot;, section on '2017 WHO classification for pancreatic neoplasms'</a>.) </p><p>Histologically, most gastrinomas are well-differentiated NETs with few mitoses and a histologic appearance that is similar to that of other pancreatic NETs. The cells are arranged in a solid, trabecular, gyriform, or glandular pattern, with fairly uniform nuclei, salt-and-pepper chromatin, and finely granular cytoplasm. As with other pancreatic NETs, the degree of malignancy cannot be predicted by morphologic appearance alone. The cells produce abundant neurosecretory granules, as reflected in the strong and diffuse immunohistochemical expression of neuroendocrine markers such as synaptophysin and chromogranin. Gastrin is the predominant peptide within the secretory granules of gastrinoma cells, but other neuroendocrine peptides such as vasoactive intestinal peptide and glucagon can sometimes be identified as well. The designation of the tumor as a gastrinoma is based upon the presence of a clinical syndrome that results from tumor production and secretion of gastrin, and not by its morphologic appearance or the presence of gastrin in the secretory granules. If a tumor stains for gastrin but does not produce symptoms of Zollinger-Ellison syndrome, it should not be considered a gastrinoma. (See <a href=\"topic.htm?path=pathology-classification-and-grading-of-neuroendocrine-neoplasms-arising-in-the-digestive-system#H799428\" class=\"medical medical_review\">&quot;Pathology classification, and grading of neuroendocrine neoplasms arising in the digestive system&quot;, section on 'Functionality and nomenclature'</a>.)</p><p class=\"headingAnchor\" id=\"H565716091\"><span class=\"h1\">PATHOPHYSIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Excessive gastrin secretion from a gastrinoma results in high gastric acid output due to the trophic action of gastrin on parietal cells and histamine-secreting enterochromaffin-like (ECL) cells (<a href=\"image.htm?imageKey=GAST%2F78549\" class=\"graphic graphic_picture graphicRef78549 \">picture 1</a>). In addition, gastrin stimulates parietal cells largely via the release of histamine. (See <a href=\"topic.htm?path=physiology-of-gastric-acid-secretion\" class=\"medical medical_review\">&quot;Physiology of gastric acid secretion&quot;</a>.)</p><p>Chronic diarrhea in Zollinger-Ellison syndrome results from the following [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/6\" class=\"abstract_t\">6</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The high volume of gastric acid secretion that cannot be fully reabsorbed by the small intestine and colon.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The rate of gastric acid secretion exceeds the neutralizing capacity of pancreatic bicarbonate secretion, resulting in an exceptionally low pH of intestinal contents. The low pH inactivates pancreatic digestive enzymes, interfering with the emulsification of fat by bile acids, and damaging intestinal epithelial cells and villi. Maldigestion and malabsorption both result in steatorrhea.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Extremely high serum gastrin concentrations inhibit the absorption of sodium and water by the small intestine, thereby adding a secretory component to the diarrhea.</p><p/><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span></p><p class=\"headingAnchor\" id=\"H60295009\"><span class=\"h2\">Clinical presentation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Abdominal pain (75 percent) and chronic diarrhea (73 percent) are the most common symptoms in patients with Zollinger-Ellison syndrome (ZES) [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/14\" class=\"abstract_t\">14</a>]. Nearly half of patients have heartburn due to gastroesophageal reflux (<a href=\"image.htm?imageKey=GAST%2F82168\" class=\"graphic graphic_figure graphicRef82168 \">figure 1</a>). Other symptoms include weight loss (17 percent) and gastrointestinal bleeding (25 percent).</p><p>Approximately 1 to 10 percent of patients, especially with metastatic disease or multiple endocrine neoplasia type 1 (MEN1), have symptoms due to a second hormonal syndrome (eg, VIPoma, somatostatinoma, glucagonoma, ACTH) [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/15\" class=\"abstract_t\">15</a>]. (See <a href=\"topic.htm?path=epidemiology-and-clinical-manifestations-of-cushings-syndrome#H2\" class=\"medical medical_review\">&quot;Epidemiology and clinical manifestations of Cushing's syndrome&quot;, section on 'Clinical manifestations'</a> and <a href=\"topic.htm?path=somatostatinoma-clinical-manifestations-diagnosis-and-management#H2\" class=\"medical medical_review\">&quot;Somatostatinoma: Clinical manifestations, diagnosis, and management&quot;, section on 'Clinical manifestations'</a> and <a href=\"topic.htm?path=vipoma-clinical-manifestations-diagnosis-and-management#H3\" class=\"medical medical_review\">&quot;VIPoma: Clinical manifestations, diagnosis, and management&quot;, section on 'Clinical features'</a> and <a href=\"topic.htm?path=glucagonoma-and-the-glucagonoma-syndrome#H4\" class=\"medical medical_review\">&quot;Glucagonoma and the glucagonoma syndrome&quot;, section on 'Clinical features'</a>.)</p><p class=\"headingAnchor\" id=\"H17088667\"><span class=\"h2\">Endoscopic features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Over 90 percent of patients with ZES develop peptic ulcers [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/16\" class=\"abstract_t\">16</a>]. Patients with ZES, like those with sporadic peptic ulcer disease, often present with solitary ulcers less than 1 cm in diameter. Approximately 75 percent of ulcers are in the first portion of the duodenum, 14 percent in the distal duodenum, and 11 percent in the jejunum [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/17\" class=\"abstract_t\">17</a>]. Ulcers are more likely to be refractory to proton pump inhibitor therapy and to recur as compared with patients with sporadic ulcer disease. Over 90 percent of patients with ZES often have prominent gastric folds. Patients may also have evidence of reflux esophagitis. However, strictures of the esophagus, pylorus, or duodenum are present in less than 10 percent of patients [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/14\" class=\"abstract_t\">14</a>]. </p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Zollinger-Ellison syndrome (ZES) should be suspected in patients with multiple or refractory peptic ulcers; ulcers distal to the duodenum; peptic ulcer disease and diarrhea, enlarged gastric folds, or multiple endocrine neoplasia type 1 (MEN1) (<a href=\"image.htm?imageKey=GAST%2F50291\" class=\"graphic graphic_table graphicRef50291 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/18\" class=\"abstract_t\">18</a>]. ZES should also be suspected in patients with peptic ulcer disease and a family history of peptic ulcer disease or MEN1. The diagnosis is established by demonstrating an elevated basal or stimulated gastrin concentration.</p><p class=\"headingAnchor\" id=\"H565716279\"><span class=\"h2\">Evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Initial evaluation in a patient with suspected ZES is with measurement of fasting serum gastrin concentration. In patients with elevated gastrin levels that are not diagnostic for ZES, we perform a <a href=\"topic.htm?path=secretin-drug-information\" class=\"drug drug_general\">secretin</a> stimulation test. The calcium infusion study (intravenous infusion with <a href=\"topic.htm?path=calcium-gluconate-drug-information\" class=\"drug drug_general\">calcium gluconate</a>) is usually reserved for patients with gastric acid hypersecretion in whom there is a strong clinical suspicion of gastrinoma despite a negative secretin stimulation test [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/19\" class=\"abstract_t\">19</a>]. </p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Serum gastrin concentration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Fasting serum gastrin should be measured in any patient suspected of having ZES [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/6\" class=\"abstract_t\">6</a>]. A serum gastrin value greater than 10 times the upper limit of normal (1000 <span class=\"nowrap\">pg/mL)</span> in the presence of a gastric pH below 2 is diagnostic of ZES. Higher levels are more likely with pancreatic (compared with duodenal) tumors, larger tumor size, and with metastatic disease [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/6\" class=\"abstract_t\">6</a>]. Measurement of gastric pH on a single specimen is important to exclude secondary hypergastrinemia due to achlorhydria (eg, atrophic gastritis, renal failure, vagotomy). In such cases the serum gastrin level can exceed 1000 <span class=\"nowrap\">pg/mL,</span> but the gastric pH is &gt;2.</p><p>Approximately two-thirds of patients with ZES have serum gastrin concentrations less than 10 times the upper limit of normal (between 110 and 1000 <span class=\"nowrap\">pg/mL)</span> [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/6\" class=\"abstract_t\">6</a>]. This degree of hypergastrinemia is nonspecific and can also be present in patients with increased gastric acid secretion (eg, antral G-cell hyperplasia, gastric outlet obstruction, and retained gastric antrum). Patients receiving proton pump inhibitors (PPIs) generally have elevated serum gastrin levels. Fasting serum gastrin levels can fluctuate even within the same patient, and elevated levels should be rechecked. (See <a href=\"#H60295066\" class=\"local\">'Differential diagnosis'</a> below.) </p><p>Commercial immunoassay kits in current use vary in their accuracy [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/20\" class=\"abstract_t\">20</a>]. In one study that evaluated 12 different commercial assay kits, four of the kits returned falsely low results in 20 to 80 percent of patients [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/20\" class=\"abstract_t\">20</a>]. False negatives are most likely to occur at relatively low gastrin concentrations, with most assays accurately detecting patients with ZES whose serum gastrin concentrations are greater than 400 <span class=\"nowrap\">pmol/L</span> (845 <span class=\"nowrap\">pg/mL)</span>. </p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Secretin stimulation test</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The <a href=\"topic.htm?path=secretin-drug-information\" class=\"drug drug_general\">secretin</a> stimulation test is used to differentiate patients with gastrinomas from other causes of hypergastrinemia. Secretin stimulates the release of gastrin by gastrinoma cells, and patients with ZES tumors have a dramatic rise in serum gastrin. In contrast, normal gastric G cells are inhibited by secretin. </p><p>False-negative response can occur in 6 to 20 percent of patients [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/21\" class=\"abstract_t\">21</a>]. False-positive results occurred in 15 to 39 percent of patients with achlorhydria induced by PPIs or due to chronic atrophic gastritis [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/22\" class=\"abstract_t\">22</a>]. However, if PPIs are discontinued abruptly, patients with ZES are at high risk to develop complications (such as acute bleeding and perforation) during the interim week [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/23\" class=\"abstract_t\">23</a>]. Discontinuation of a PPI in a patient suspected of having ZES should be done by an experienced provider. One week prior to the <a href=\"topic.htm?path=secretin-drug-information\" class=\"drug drug_general\">secretin</a> study we substitute PPIs with high-dose H2 receptor antagonists (eg, <a href=\"topic.htm?path=ranitidine-drug-information\" class=\"drug drug_general\">ranitidine</a> 450 to 750 mg every 6 hours until 24 hours prior to the test). Oral antacids are then taken as needed until midnight prior to the study. Patients should be advised to seek immediate medical attention for nasogastric aspiration if they develop significant exacerbation of ZES symptoms (eg, vomiting, pain, diarrhea) during the taper period [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/24\" class=\"abstract_t\">24</a>].</p><p>The <a href=\"topic.htm?path=secretin-drug-information\" class=\"drug drug_general\">secretin</a> stimulation test is performed by administering 0.4 <span class=\"nowrap\">micrograms/kg</span> by rapid infusion intravenously over one minute; a baseline serum gastrin is measured twice before the secretin is administered and 2, 5, 10, and 30 minutes later. Several criteria have been proposed to define a positive test; an increase in gastrin levels of greater than 120 <span class=\"nowrap\">pg/mL</span> over basal fasting levels has a sensitivity and a specificity of 94 and 100 percent, respectively [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/19,25\" class=\"abstract_t\">19,25</a>]. Serum gastrin levels usually peak by 10 minutes (<a href=\"image.htm?imageKey=ENDO%2F66223\" class=\"graphic graphic_figure graphicRef66223 \">figure 2</a>).</p><p>The <a href=\"topic.htm?path=secretin-drug-information\" class=\"drug drug_general\">secretin</a> stimulation test should not be performed in patients with severe manifestations of ZES. This includes patients with severe abdominal pain, vomiting and diarrhea to the point of dehydration, or endoscopic findings of thickened gastric folds or multiple ulcers, as they are at particular risk for life-threatening consequences of discontinuing acid suppression. In such patients, tumor localization studies should be performed. (See <a href=\"#H11\" class=\"local\">'Tumor localization'</a> below.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Calcium infusion study</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The calcium infusion study (intravenous infusion with <a href=\"topic.htm?path=calcium-gluconate-drug-information\" class=\"drug drug_general\">calcium gluconate</a> followed by peripheral venous sampling) is considerably less sensitive and specific compared with the <a href=\"topic.htm?path=secretin-drug-information\" class=\"drug drug_general\">secretin</a> stimulation test for diagnostic purposes, and more cumbersome to perform [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/19\" class=\"abstract_t\">19</a>]. However, in ZES patients with a negative secretin test, 38 to 50 percent have a positive calcium test [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/19\" class=\"abstract_t\">19</a>]. </p><p>The test is performed by infusing <a href=\"topic.htm?path=calcium-gluconate-drug-information\" class=\"drug drug_general\">calcium gluconate</a> (5 <span class=\"nowrap\">mg/kg</span> body weight per hour for three hours) and determining serum gastrin and calcium levels every 30 minutes. Infusion is associated with an increase in serum gastrin and calcium levels in patients with gastrinoma. Positive responses are usually observed between 120 and 180 minutes [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/26\" class=\"abstract_t\">26</a>]. An increase in fasting serum gastrin of &ge;395 <span class=\"nowrap\">pg/mL</span> has a sensitivity and specificity of 54 to 62 percent and 100 percent, respectively. A &ge;50 percent increase in serum gastrin has a sensitivity and specificity of 78 and 83 percent, respectively [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/19\" class=\"abstract_t\">19</a>].</p><p class=\"headingAnchor\" id=\"H17088817\"><span class=\"h2\">Other</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other tests that are supportive of the diagnosis of ZES but are rarely performed include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Serum chromogranin A </strong>&ndash; Serum chromogranin A is elevated in most patients with gastrinomas, and the level of elevation tends to correlate with tumor volume [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/27\" class=\"abstract_t\">27</a>]. In contrast to other neuroendocrine tumors, very high levels of chromogranin A can be seen in gastrinomas without liver metastases [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/28\" class=\"abstract_t\">28</a>]. Chromogranin A levels are usually normal or near normal in patients with high gastrin levels secondary to chronic atrophic gastritis. (See <a href=\"topic.htm?path=clinical-characteristics-of-well-differentiated-neuroendocrine-carcinoid-tumors-arising-in-the-tubular-digestive-tract-lung-and-genitourinary-tract#H8\" class=\"medical medical_review\">&quot;Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the tubular digestive tract, lung, and genitourinary tract&quot;, section on 'Stomach'</a>.)</p><p/><p class=\"bulletIndent1\">However, serum chromogranin A is less sensitive for a gastrinoma as compared with fasting serum gastrin levels. In addition, elevated chromogranin A is not specific to gastrinomas and is a general marker for well-differentiated neuroendocrine tumors [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/29\" class=\"abstract_t\">29</a>]. Elevated chromogranin A levels may be seen in a number of other conditions including PPI use [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/30,31\" class=\"abstract_t\">30,31</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Gastric acid secretion studies</strong> &ndash; Gastric acid secretion studies to measure basal acid output, which were once pivotal in establishing the diagnosis of ZES, are no longer performed due to their technical difficulty [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/22\" class=\"abstract_t\">22</a>]. Basal acid output is measured by the passage of a nasogastric tube into the dependent portion of the stomach with aspiration and quantification of gastric juice production over a one-hour period. A basal acid output of &gt;15 <span class=\"nowrap\">mEq/hour</span> is supportive of the diagnosis of ZES. </p><p/><p class=\"headingAnchor\" id=\"H60295066\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Antral G-cell hyperplasia</strong> &ndash; Antral G-cell hyperplasia is a rare entity associated with increase in the number of G cells and characterized by a marked hypergastrinemia. Peptic ulcers can also be seen in patients with antral G-cell hyperplasia. However, unlike Zollinger Ellison syndrome (ZES), antral G-cell hyperplasia is characterized by a poor response to <a href=\"topic.htm?path=secretin-drug-information\" class=\"drug drug_general\">secretin</a> stimulation test, and absence of gastrinoma on imaging. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Retained antrum syndrome</strong> &ndash; Retained antrum syndrome should be suspected in patients with<strong> </strong>recurrent peptic ulceration after gastrectomy. In such cases, peptic ulcer recurrence results from incomplete excision of the gastric antrum from the duodenum. Gastrin elevation in patients with retained antrum syndrome is only modest as compared with patients with ZES, and hypergastrinemia is reversible with excision of the retained antral remnant. </p><p/><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">TUMOR LOCALIZATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>After the diagnosis of Zollinger-Ellison syndrome (ZES) is made, the gastrinoma must be located and staged. (See <a href=\"topic.htm?path=management-and-prognosis-of-the-zollinger-ellison-syndrome-gastrinoma\" class=\"medical medical_review\">&quot;Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)&quot;</a> and <a href=\"topic.htm?path=multiple-endocrine-neoplasia-type-1-treatment\" class=\"medical medical_review\">&quot;Multiple endocrine neoplasia type 1: Treatment&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tumor localization begins with an upper endoscopy if not already performed, cross-sectional imaging with helical, contrast-enhanced, triple-phase computed tomography (CT) or magnetic resonance imaging (MRI), and somatostatin receptor scintigraphy <span class=\"nowrap\">(SRS)/Gallium-68-DOTA-D-Phe1-Tyr3-Octreotate</span> (<a href=\"topic.htm?path=gallium-ga-68-dotatate-drug-information\" class=\"drug drug_general\">Gallium Ga-68 DOTATATE</a> <span class=\"nowrap\">PET/CT)</span> [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/32,33\" class=\"abstract_t\">32,33</a>]. Because of its greater sensitivity, 68-Ga DOTATATE PET imaging may be preferable to conventional SRS with 111-In pentetreotide [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/34\" class=\"abstract_t\">34</a>]. (See <a href=\"#H17088667\" class=\"local\">'Endoscopic features'</a> above and <a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms#H12145128\" class=\"medical medical_review\">&quot;Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms&quot;, section on 'Indium-111 pentetreotide (OctreoScan)'</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If <span class=\"nowrap\">CT/MRI</span> and <span class=\"nowrap\">SRS/68-Ga</span> DOTATATE <span class=\"nowrap\">PET/CT</span> are negative, and surgery is being considered, an endoscopic ultrasound (EUS) should be performed because of its greater sensitivity in detecting small tumors. EUS also permits fine-needle aspiration for histological identification. (See <a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms#H12145121\" class=\"medical medical_review\">&quot;Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms&quot;, section on 'Endoscopic ultrasonography'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We reserve invasive testing to localize the tumor with angiography or selective arterial stimulation and venous sampling with <a href=\"topic.htm?path=secretin-drug-information\" class=\"drug drug_general\">secretin</a> injection for patients who are strongly suspected of having a gastrinoma in whom imaging is negative [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/35\" class=\"abstract_t\">35</a>]. However, in some cases tumor localization can only be achieved at laparotomy by direct palpation, duodenal transillumination, or intraoperative ultrasound. (See <a href=\"#H10\" class=\"local\">'Calcium infusion study'</a> above and <a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms#H12145142\" class=\"medical medical_review\">&quot;Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms&quot;, section on 'Intraoperative localization techniques'</a>.) </p><p/><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">STAGING SYSTEM</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Two staging systems are available for pancreatic neuroendocrine tumors such as gastrinomas, one from the combined American Joint Committee on <span class=\"nowrap\">Cancer/Union</span> for International Cancer Control (UICC) [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/36\" class=\"abstract_t\">36</a>], and another proposed by the European Neuroendocrine Tumor Society (<a href=\"image.htm?imageKey=ONC%2F86409\" class=\"graphic graphic_table graphicRef86409 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/36,37\" class=\"abstract_t\">36,37</a>]. Both staging systems are highly prognostic for both relapse-free and overall survival [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/38-40\" class=\"abstract_t\">38-40</a>]. The newest update of the TNM staging classification (8<sup>th</sup> edition, 2017)has a staging system for neuroendocrine tumors of the pancreas (<a href=\"image.htm?imageKey=ONC%2F111355\" class=\"graphic graphic_table graphicRef111355 \">table 4</a>) that is separate from that used for exocrine pancreatic tumors [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/41\" class=\"abstract_t\">41</a>]. (See <a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms#H26599949\" class=\"medical medical_review\">&quot;Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms&quot;, section on 'Staging system'</a>.)</p><p class=\"headingAnchor\" id=\"H492533011\"><span class=\"h1\">ADDITIONAL EVALUATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest biochemical studies to screen for multiple endocrine neoplasia 1 (MEN1) in patients with Zollinger-Ellison syndrome (ZES), as 20 to 25 percent of patients have MEN1 and because up to 40 percent of <span class=\"nowrap\">MEN1/ZES</span> patients have no family history [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/12\" class=\"abstract_t\">12</a>]. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>All patients with ZES should have serum parathormone levels, ionized calcium levels, and prolactin levels at diagnosis and periodically thereafter [<a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/12\" class=\"abstract_t\">12</a>]. Screening for MEN1-associated tumors is discussed separately. (See <a href=\"#H2\" class=\"local\">'Epidemiology'</a> above and <a href=\"topic.htm?path=multiple-endocrine-neoplasia-type-1-clinical-manifestations-and-diagnosis#H14907078\" class=\"medical medical_review\">&quot;Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis&quot;, section on 'Screening for MEN1-associated tumors'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Individuals with a family history of MEN1, suspicious clinical or laboratory findings (eg, renal colic or nephrolithiases, history of hypercalcemia), or multiple MEN1 tumor types (parathyroid gland, anterior pituitary, and enteropancreatic) should undergo evaluation for MEN1 syndrome. The management of patients with MEN1 is discussed separately. (See <a href=\"topic.htm?path=multiple-endocrine-neoplasia-type-1-treatment\" class=\"medical medical_review\">&quot;Multiple endocrine neoplasia type 1: Treatment&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Zollinger-Ellison syndrome (ZES) is caused by secretion of gastrin by duodenal or pancreatic neuroendocrine tumors (gastrinomas). The annual incidence of gastrinomas is 0.5 to 2 per million population. Most patients are diagnosed between the ages of 20 and 50, with a higher incidence in men as compared with women. While most gastrinomas are sporadic, 20 to 30 percent occur in association with multiple endocrine neoplasia (MEN1) syndrome. Approximately 50 to 88 percent of sporadic ZES patients, and 70 to 100 percent of ZES and MEN1, have duodenal gastrinomas. (See <a href=\"#H2\" class=\"local\">'Epidemiology'</a> above and <a href=\"#H3\" class=\"local\">'Classification, nomenclature, and histology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Excessive gastrin secretion from a gastrinoma results in high gastric acid output. Chronic diarrhea results from failure of resorption of the increased gastric acid, inactivation of pancreatic enzymes, damage to intestinal epithelium, and inhibition of the absorption of sodium and water. (See <a href=\"#H3\" class=\"local\">'Classification, nomenclature, and histology'</a> above and <a href=\"#H565716091\" class=\"local\">'Pathophysiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Abdominal pain (75 percent) and diarrhea (73 percent) are the most common symptoms in patients with ZES. Nearly half of patients have heartburn due to gastroesophageal reflux (<a href=\"image.htm?imageKey=GAST%2F82168\" class=\"graphic graphic_figure graphicRef82168 \">figure 1</a>). Other symptoms include weight loss (17 percent) and gastrointestinal bleeding (25 percent). (See <a href=\"#H60295009\" class=\"local\">'Clinical presentation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Over 90 percent of patients with ZES develop peptic ulcers. Patients with ZES often present with solitary ulcers less than 1 cm in diameter. Approximately 75 percent of ulcers are in the first portion of the duodenum, 14 percent in the distal duodenum, and 11 percent in the jejunum. Ulcers in ZES may be refractory to proton pump inhibitors and recur much more often as compared with patients with sporadic ulcer disease. On upper endoscopy, patients with ZES may have prominent gastric folds and evidence of reflux esophagitis. However, strictures of the esophagus, pylorus, or duodenum are present in less than 10 percent of patients. (See <a href=\"#H17088667\" class=\"local\">'Endoscopic features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>ZES should be suspected in patients with multiple or refractory peptic ulcers; ulcers distal to the duodenum; peptic ulcer disease and diarrhea, enlarged gastric folds, an endocrinopathy or multiple endocrine neoplasia type 1 (<a href=\"image.htm?imageKey=GAST%2F50291\" class=\"graphic graphic_table graphicRef50291 \">table 2</a>). ZES should also be suspected in patients with peptic ulcer disease and a family history of peptic ulcer disease or MEN1. The diagnosis is established by demonstrating an elevated basal or stimulated gastrin concentration. (See <a href=\"#H5\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tumor localization begins with an upper endoscopy if not already performed, cross-sectional imaging with helical, contrast-enhanced, triple-phase computed tomography (CT) or magnetic resonance imaging (MRI), and somatostatin receptor scintigraphy <span class=\"nowrap\">(SRS)/68-gallium-DOTA-D-Phe1-Tyr3-octreotate</span> (<a href=\"topic.htm?path=gallium-ga-68-dotatate-drug-information\" class=\"drug drug_general\">Gallium Ga-68 DOTATATE</a> <span class=\"nowrap\">PET/CT</span>. If CT or MRI and <span class=\"nowrap\">SRS/68-Ga</span> DOTATATE <span class=\"nowrap\">PET/CT</span> are negative, and surgery is being considered, endoscopic ultrasound should be performed to localize the tumor. We reserve invasive testing to localize the tumor with angiography or selective arterial stimulation and venous sampling with <a href=\"topic.htm?path=secretin-drug-information\" class=\"drug drug_general\">secretin</a> injection for patients who are strongly suspected of having a gastrinoma in whom imaging is negative. However, in some cases tumor localization can only be achieved at laparotomy, by direct palpation, duodenal transillumination, or intraoperative ultrasound. (See <a href=\"#H11\" class=\"local\">'Tumor localization'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>All patients with ZES should be screened for MEN1 syndrome with serum parathormone levels, ionized calcium levels, and prolactin levels at diagnosis, and periodically thereafter. Individuals with a family history of MEN1, suspicious clinical or laboratory findings (eg, renal colic or nephrolithiases, history of hypercalcemia), or multiple MEN1 tumor types (parathyroid gland, anterior pituitary, and enteropancreatic) should undergo evaluation for MEN1 syndrome. (See <a href=\"#H492533011\" class=\"local\">'Additional evaluation'</a> above and <a href=\"topic.htm?path=multiple-endocrine-neoplasia-type-1-clinical-manifestations-and-diagnosis#H4058938\" class=\"medical medical_review\">&quot;Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1092278720\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The UpToDate editorial staff would like to thank Dr. Stephen E. Goldfinger, MD, for his past contributions as an author to previous versions of this topic review. </p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/1\" class=\"nounderline abstract_t\">ZOLLINGER RM, ELLISON EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955; 142:709.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/2\" class=\"nounderline abstract_t\">Ellison EC, Johnson JA. The Zollinger-Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations. Curr Probl Surg 2009; 46:13.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/3\" class=\"nounderline abstract_t\">Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010; 39:735.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/4\" class=\"nounderline abstract_t\">Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008; 135:1469.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/5\" class=\"nounderline abstract_t\">Oberg K. Pancreatic endocrine tumors. Semin Oncol 2010; 37:594.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/6\" class=\"nounderline abstract_t\">Berna MJ, Hoffmann KM, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 2006; 85:295.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/7\" class=\"nounderline abstract_t\">Norton JA. Neuroendocrine tumors of the pancreas and duodenum. Curr Probl Surg 1994; 31:77.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/8\" class=\"nounderline abstract_t\">Isenberg JI, Walsh JH, Grossman MI. Zollinger-Ellison syndrome. Gastroenterology 1973; 65:140.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/9\" class=\"nounderline abstract_t\">Zhuang Z, Vortmeyer AO, Pack S, et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 1997; 57:4682.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/10\" class=\"nounderline abstract_t\">Weber HC, Venzon DJ, Lin JT, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995; 108:1637.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/11\" class=\"nounderline abstract_t\">Norton JA, Alexander HR, Fraker DL, et al. Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study. Ann Surg 2003; 237:650.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/12\" class=\"nounderline abstract_t\">Jensen RT, Cadiot G, Brandi ML, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012; 95:98.</a></li><li class=\"breakAll\">Ohike N, Adsay NV, La Rosa S, et al.. Mixed neuroendocrine-non-neuroendocrine neoplasms.. In: WHO Classification of Tumours of Endocrine Organs, 4th ed, Lloyd RV, Osamura RY, Kloppel G, Rosai J (Eds), IARC Press, Lyon 2017. p.238.</li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/14\" class=\"nounderline abstract_t\">Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore) 2000; 79:379.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/15\" class=\"nounderline abstract_t\">de Mestier L, Hentic O, Cros J, et al. Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors: a case-series study. Ann Intern Med 2015; 162:682.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/16\" class=\"nounderline abstract_t\">Deveney CW, Deveney KE. Zollinger-Ellison syndrome (gastrinoma). Current diagnosis and treatment. Surg Clin North Am 1987; 67:411.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/17\" class=\"nounderline abstract_t\">Meko JB, Norton JA. Management of patients with Zollinger-Ellison syndrome. Annu Rev Med 1995; 46:395.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/18\" class=\"nounderline abstract_t\">Orloff SL, Debas HT. Advances in the management of patients with Zollinger-Ellison syndrome. Surg Clin North Am 1995; 75:511.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/19\" class=\"nounderline abstract_t\">Berna MJ, Hoffmann KM, Long SH, et al. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore) 2006; 85:331.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/20\" class=\"nounderline abstract_t\">Rehfeld JF, Gingras MH, Bardram L, et al. The Zollinger-Ellison syndrome and mismeasurement of gastrin. Gastroenterology 2011; 140:1444.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/21\" class=\"nounderline abstract_t\">Kuiper P, Biemond I, Masclee AA, et al. Diagnostic efficacy of the secretin stimulation test for the Zollinger-Ellison syndrome: an intra-individual comparison using different dosages in patients and controls. Pancreatology 2010; 10:14.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/22\" class=\"nounderline abstract_t\">Shah P, Singh MH, Yang YX, Metz DC. Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome. Pancreas 2013; 42:932.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/23\" class=\"nounderline abstract_t\">Poitras P, Gingras MH, Rehfeld JF. The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol 2012; 10:199.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/24\" class=\"nounderline abstract_t\">Metz DC. Diagnosis of the Zollinger&ndash;Ellison syndrome. Clin Gastroenterol Hepatol 2012; 10:126.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/25\" class=\"nounderline abstract_t\">McGuigan JE, Wolfe MM. Secretin injection test in the diagnosis of gastrinoma. Gastroenterology 1980; 79:1324.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/26\" class=\"nounderline abstract_t\">Frucht H, Howard JM, Slaff JI, et al. Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study. Ann Intern Med 1989; 111:713.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/27\" class=\"nounderline abstract_t\">Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997; 82:2622.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/28\" class=\"nounderline abstract_t\">Tomassetti P, Migliori M, Simoni P, et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol 2001; 13:55.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/29\" class=\"nounderline abstract_t\">Modlin IM, Gustafsson BI, Moss SF, et al. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010; 17:2427.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/30\" class=\"nounderline abstract_t\">Sanduleanu S, Stridsberg M, Jonkers D, et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther 1999; 13:145.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/31\" class=\"nounderline abstract_t\">Giusti M, Sidoti M, Augeri C, et al. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol 2004; 150:299.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/32\" class=\"nounderline abstract_t\">Deppen SA, Liu E, Blume JD, et al. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. J Nucl Med 2016; 57:708.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/33\" class=\"nounderline abstract_t\">Sadowski SM, Neychev V, Millo C, et al. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol 2016; 34:588.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/34\" class=\"nounderline abstract_t\">Srirajaskanthan R, Kayani I, Quigley AM, et al. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med 2010; 51:875.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/35\" class=\"nounderline abstract_t\">Thom AK, Norton JA, Doppman JL, et al. Prospective study of the use of intraarterial secretin injection and portal venous sampling to localize duodenal gastrinomas. Surgery 1992; 112:1002.</a></li><li class=\"breakAll\">AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th ed, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York  Vol 2010, p.241.</li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/37\" class=\"nounderline abstract_t\">Rindi G, Kl&ouml;ppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449:395.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/38\" class=\"nounderline abstract_t\">Strosberg JR, Cheema A, Weber JM, et al. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg 2012; 256:321.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/39\" class=\"nounderline abstract_t\">Strosberg JR, Cheema A, Weber J, et al. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol 2011; 29:3044.</a></li><li><a href=\"https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/abstract/40\" class=\"nounderline abstract_t\">Cho JH, Ryu JK, Song SY, et al. Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumors: A Retrospective Nationwide Multicenter Study in South Korea. Pancreas 2016; 45:941.</a></li><li class=\"breakAll\">Bergsland EK, Woltering EA, Rindo G. Neuroendocrine tumors of the pancreas. In: AJCC Cancer Staging Manual, 8th, Amin MB (Ed), AJCC, Chicago 2017. p.407.</li></ol></div><div id=\"topicVersionRevision\">Topic 2627 Version 18.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H13\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">CLASSIFICATION, NOMENCLATURE, AND HISTOLOGY</a></li><li><a href=\"#H565716091\" id=\"outline-link-H565716091\">PATHOPHYSIOLOGY</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H60295009\" id=\"outline-link-H60295009\">Clinical presentation</a></li><li><a href=\"#H17088667\" id=\"outline-link-H17088667\">Endoscopic features</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">DIAGNOSIS</a><ul><li><a href=\"#H565716279\" id=\"outline-link-H565716279\">Evaluation</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Serum gastrin concentration</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Secretin stimulation test</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Calcium infusion study</a></li><li><a href=\"#H17088817\" id=\"outline-link-H17088817\">Other</a></li></ul></li><li><a href=\"#H60295066\" id=\"outline-link-H60295066\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">TUMOR LOCALIZATION</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">STAGING SYSTEM</a></li><li><a href=\"#H492533011\" id=\"outline-link-H492533011\">ADDITIONAL EVALUATION</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H1092278720\" id=\"outline-link-H1092278720\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"GAST/2627|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/82168\" class=\"graphic graphic_figure\">- Symptoms in ZES</a></li><li><a href=\"image.htm?imageKey=ENDO/66223\" class=\"graphic graphic_figure\">- Secretin test for gastrinoma</a></li></ul></li><li><div id=\"GAST/2627|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/78549\" class=\"graphic graphic_picture\">- Zollinger Ellison Light</a></li></ul></li><li><div id=\"GAST/2627|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/115945\" class=\"graphic graphic_table\">- 2017 WHO classific grading panc neuroendo neoplasms</a></li><li><a href=\"image.htm?imageKey=GAST/50291\" class=\"graphic graphic_table\">- Clincial features of ZES</a></li><li><a href=\"image.htm?imageKey=ONC/86409\" class=\"graphic graphic_table\">- ENETS staging system for pancreatic NETS</a></li><li><a href=\"image.htm?imageKey=ONC/111355\" class=\"graphic graphic_table\">- Neuroendocrine tumors of the pancreas TNM 2017</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms\" class=\"medical medical_review\">Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-characteristics-of-well-differentiated-neuroendocrine-carcinoid-tumors-arising-in-the-tubular-digestive-tract-lung-and-genitourinary-tract\" class=\"medical medical_review\">Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the tubular digestive tract, lung, and genitourinary tract</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-clinical-manifestations-of-cushings-syndrome\" class=\"medical medical_review\">Epidemiology and clinical manifestations of Cushing's syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=glucagonoma-and-the-glucagonoma-syndrome\" class=\"medical medical_review\">Glucagonoma and the glucagonoma syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-and-prognosis-of-the-zollinger-ellison-syndrome-gastrinoma\" class=\"medical medical_review\">Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=multiple-endocrine-neoplasia-type-1-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=multiple-endocrine-neoplasia-type-1-treatment\" class=\"medical medical_review\">Multiple endocrine neoplasia type 1: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathology-classification-and-grading-of-neuroendocrine-neoplasms-arising-in-the-digestive-system\" class=\"medical medical_review\">Pathology classification, and grading of neuroendocrine neoplasms arising in the digestive system</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=physiology-of-gastric-acid-secretion\" class=\"medical medical_review\">Physiology of gastric acid secretion</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=somatostatinoma-clinical-manifestations-diagnosis-and-management\" class=\"medical medical_review\">Somatostatinoma: Clinical manifestations, diagnosis, and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vipoma-clinical-manifestations-diagnosis-and-management\" class=\"medical medical_review\">VIPoma: Clinical manifestations, diagnosis, and management</a></li></ul></div></div>","javascript":null}